Zaprinast

Zaprinast

Zaprinast

Chemical compound

Zaprinast was an unsuccessful clinical drug candidate that was a precursor to the chemically related PDE5 inhibitors, such as sildenafil (Viagra), which successfully reached the market. It is a phosphodiesterase inhibitor,[1] selective for the subtypes PDE5, PDE6, PDE9 and PDE11. IC50 values are 0.76, 0.15, 29.0, and 12.0 μM, respectively.[2][3]

Quick Facts Names, Identifiers ...

Zaprinast inhibits the growth of asexual blood-stage malaria parasites (P. falciparum) in vitro with an ED50 value of 35 μM, and inhibits PfPDE1, a P. falciparum cGMP-specific phosphodiesterase, with an IC50 value of 3.8 μM.[4]

Zaprinast has also been shown to activate the orphan G-protein coupled receptor known as GPR35, both in rats and humans,[5] and to inhibit the mitochondrial pyruvate carrier. [6]

References

  1. [1]
    Choi, SH; Choi, DH; Song, KS; Shin, KH; Chun, BG (2002). "Zaprinast, an inhibitor of cGMP-selective phosphodiesterases, enhances the secretion of TNF-alpha and IL-1beta and the expression of iNOS and MHC class II molecules in rat microglial cells". Journal of Neuroscience Research. 67 (3): 411–21. doi:10.1002/jnr.10102. PMID 11813247. S2CID 24513289.
  2. [2]
    Taniguchi, Y.; Tonaikachi, H.; Shinjo, K. (2006). "Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35". FEBS Letters. 580 (21): 5003–5008. doi:10.1016/j.febslet.2006.08.015. PMID 16934253. S2CID 43142927.
  3. [3]
    Keswani, A. N.; Peyton, K. J.; Durante, W.; Schafer, A. I.; Tulis, D. A. (2009). "The Cyclic GMP Modulators YC-1 and Zaprinast Reduce Vessel Remodeling Through Antiproliferative and Proapoptotic Effects". Journal of Cardiovascular Pharmacology and Therapeutics. 14 (2): 116–124. doi:10.1177/1074248409333266. PMC 2702762. PMID 19342499.
  4. [4]
    Keizo Yuasa; Fumika Mi-Ichi; Tamaki Kobayashi; Masaya Yamanouchi; Jun Kotera; Kiyoshi Kita; Kenji Omori (2005). "PfPDE1, a novel cGMP-specific phosphodiesterase from the human malaria parasite Plasmodium falciparum". Biochem. J. 392 (Pt 1): 221–9. doi:10.1042/BJ20050425. PMC 1317681. PMID 16038615.
  5. [5]
    Yasuhito Taniguchi; Hiroko Tonai-Kachi; Katsuhiro Shinjo (2006). "Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35". FEBS Letters. 580 (21): 5003–5008. doi:10.1016/j.febslet.2006.08.015. PMID 16934253. S2CID 43142927.
  6. [6]
    Jianhai Du; Whitney M Cleghorn; Laura Contreras; Ken Lindsay; Austin M Rountree; Andrei O Chertov; Sally J Turner; Ayse Sahaboglu; Jonathan Linton; Martin Sadilek; Jorgina Satrustegui; Ian R Sweet; Francois Paquet-Durand; James B Hurley (2013). "Inhibition of mitochondrial pyruvate transport by zaprinast causes massive accumulation of aspartate at the expense of glutamate in the retina". J Biol Chem. 288 (50): 36129–36140. doi:10.1074/jbc.M113.507285. PMC 3861660. PMID 24187136. S2CID 9429684.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Zaprinast, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.